STTK Shattuck Labs, Inc.
Price Chart
Executive Summary
Shattuck Labs reported full-year 2025 financial results showing reduced net loss of $48.8 million (down from $75.4M in 2024) due to lower R&D and G&A expenses following pipeline restructuring. The company raised $21.4 million in Q1 2026 through an ATM offering, extending its cash runway into 2029. Clinical progress includes advancement of its lead candidate SL-325 into Phase 1 data readout (expected Q2 2026) and planned Phase 2 initiation in Crohn's disease (Q3 2026).
Key Financial Metrics
Actionable Insight
Monitor upcoming Phase 1 data readout for SL-325 in Q2 2026 as the key near-term catalyst; the extended cash runway reduces near-term dilution risk
Key Facts
- Net loss decreased to $48.8M in 2025 from $75.4M in 2024 due to R&D program discontinuation and workforce reductions
- Cash and investments totaled $78.1M as of December 31, 2025, with $94.5M unaudited as of February 28, 2026 after $21.4M ATM raise
- Cash runway now extends into 2029 based on current plans
- SL-325 Phase 1 trial completed enrollment with data expected in Q2 2026
- Phase 2 trial in Crohn's disease expected to initiate in Q3 2026
- Lead bispecific antibody entered IND-enabling activities
Financial Impact
Reduced annual net loss by $26.6 million while extending cash runway to 2029 through $21.4 million capital raise
Risk Factors
- Clinical development risk for SL-325 with data readout pending
- Dependence on successful clinical outcomes to maintain valuation given pre-revenue status
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-014987 |
| Document: sttk-20260305.htm | 0001628280-26-014987 |
| Document: 0001628280-26-014987-index-headers.html | 0001628280-26-014987 |
| Document: 0001628280-26-014987-index.html | 0001628280-26-014987 |
| Document: 0001628280-26-014987.txt | 0001628280-26-014987 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
8-K
| $4.13 awaiting T+1 | awaiting T+1 | — | $4.94 (−19.61%) |
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $4.13 awaiting T+1 | awaiting T+1 | — | $4.94 (−19.61%) |
|
Jun 11, 2026
3d ago
|
424B5
| $4.13 awaiting T+1 | awaiting T+1 | — | $4.94 (−19.61%) |
|
Jun 10, 2026
5d ago
|
Press Release
| $4.27 awaiting T+1 | awaiting T+1 | — | $4.94 (−15.69%) |
|
Jun 9, 2026
5d ago
|
424B5
| $4.27 awaiting T+1 | awaiting T+1 | — | $4.94 (−15.69%) |
|
Jun 9, 2026
5d ago
|
8-K
| $4.27 awaiting T+1 | awaiting T+1 | — | $4.94 (+15.69%) |
|
Jun 2, 2026
12d ago
|
8-K
| $4.75 $4.80 | ▲ +1.05% | ▲ +0.65% | $4.94 (+4.00%) |
|
May 15, 2026
4w ago
|
Insider Cluster
| $6.26 $5.97 | ▼ −4.63% | ▼ −4.57% | $4.94 (−21.09%) |
|
May 12, 2026
4w ago
|
Insider Cluster
| $6.62 $6.75 | ▲ +1.96% | ▲ +1.39% | $4.94 (−25.38%) |
|
May 7, 2026
5w ago
|
8-K
| $6.26 $6.85 | ▲ +9.42% | ▲ +8.59% | $4.94 (−21.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access